Response results
| . | MPD cohort (n = 52) . | Overall (N = 84) . |
|---|---|---|
| Best response, n (%) | ||
| Stringent complete response | 2 (3.8) | 3 (3.6) |
| Complete response | 1 (1.9) | 1 (1.2) |
| Very good partial response | 19 (36.5) | 30 (35.7) |
| Partial response | 18 (34.6) | 24 (28.6) |
| Minimal response | 0 (0) | 6 (7.1) |
| Stable disease | 3 (5.8) | 7 (8.3) |
| Progressive disease | 5 (9.6) | 6 (7.1) |
| Not evaluable | 4 (7.7) | 7 (8.3) |
| Overall response rate, n (%)* | 40 (76.9) | 58 (69.0) |
| Median time to response, months (range) | 0.95 (0.5-4.6) | 0.95 (0.5-29.9) |
| Median duration, months (95% CI)† | 22.1 (9.5-38.0) | 18.8 (9.7-33.4) |
| Clinical benefit rate, n (%)‡ | 40 (76.9) | 64 (76.2) |
| Median duration, months (95% CI)† | 22.6 (9.5-39.8) | 18.8 (9.7-26.1) |
| . | MPD cohort (n = 52) . | Overall (N = 84) . |
|---|---|---|
| Best response, n (%) | ||
| Stringent complete response | 2 (3.8) | 3 (3.6) |
| Complete response | 1 (1.9) | 1 (1.2) |
| Very good partial response | 19 (36.5) | 30 (35.7) |
| Partial response | 18 (34.6) | 24 (28.6) |
| Minimal response | 0 (0) | 6 (7.1) |
| Stable disease | 3 (5.8) | 7 (8.3) |
| Progressive disease | 5 (9.6) | 6 (7.1) |
| Not evaluable | 4 (7.7) | 7 (8.3) |
| Overall response rate, n (%)* | 40 (76.9) | 58 (69.0) |
| Median time to response, months (range) | 0.95 (0.5-4.6) | 0.95 (0.5-29.9) |
| Median duration, months (95% CI)† | 22.1 (9.5-38.0) | 18.8 (9.7-33.4) |
| Clinical benefit rate, n (%)‡ | 40 (76.9) | 64 (76.2) |
| Median duration, months (95% CI)† | 22.6 (9.5-39.8) | 18.8 (9.7-26.1) |